Skip to content

Osimertinib in resected EGFR-mutated NSCLC

One-paragraph summary

ADAURA randomized completely resected stage IB–IIIA NSCLC with EGFR exon-19 deletion or L858R to osimertinib or placebo for three years after optional adjuvant chemotherapy. The initial report found DFS HR 0.17 in stage II–IIIA and 0.20 in the overall stage IB–IIIA population (PMID 32955177); mature follow-up reported OS HR 0.49 and five-year OS 88% versus 78% in stage IB–IIIA (PMID 37272535).

Key findings

  • Genotype-specific adjuvant randomized trial after complete resection.
  • Three-year planned osimertinib duration.
  • Stage II–IIIA DFS HR: 0.17 at initial report.
  • Overall stage IB–IIIA DFS HR: 0.20.
  • Mature OS HR: 0.49; five-year OS 88% versus 78%.
  • CNS recurrence reduction was a clinically important component.

Limitations

  • Adjuvant chemotherapy was optional and not randomized.
  • Placebo control does not answer surveillance plus guaranteed osimertinib at relapse.
  • Optimal duration and MRD selection remain unknown.
  • Outcomes after relapse following adjuvant osimertinib require longer study.

Why it matters

ADAURA moved comprehensive molecular testing into resected adenocarcinoma and established that targeted therapy can improve survival in the adjuvant setting, not merely postpone radiographic recurrence.

Cited by wiki pages

  • Overview
  • EGFR disease
  • Early-stage and perioperative therapy
  • Guidelines